Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Imagabalin in Generalized Anxiety Disorder
NCT00542685Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of imagabalin in generalized anxiety disorder (GAD) (4 arms), sponsored by Pfizer. Primary endpoints: Change in Hamilton Anxiety Rating Scale Total Score at 8 weeks and Safety and Tolerability at 8 weeks. Started Oct 2007; status: completed.
02
Drugs
imagabalin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00542685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542685.